21.1 Introduction
Erythropoietic protoporphyria (EPP) is a rare genetic disorder of heme biosynthesis characterized clinically by acute pain on sun exposure.
21.2 Epidemiology
EPP is the most common porphyria of childhood. It may present or be first diagnosed in adolescence.
Inheritance is autosomal recessive. It is caused by a combination of loss of function mutations and low expression allelic variants in the FECH gene. Deficiency of the enzyme ferrochelatase leads to accumulation of protoporphyrin IX in circulating erythrocytes. Following exposure to sunlight, these protoporphyrins cause acute cutaneous phototoxicity. Accumulation of protoporphyrins in the liver may result in hepatotoxicity and cholestasis.
X-linked protoporphyria, caused by mutations in ALAS2, has a similar clinical presentation to EPP.
21.3 Clinical Findings

Erythema of dorsal hands in EPP
21.4 Laboratory
Laboratory investigation shows elevated levels of free erythrocyte protoporphyrin. The diagnosis may be confirmed by sequencing of the FECH (or ALAS2) gene. Patients require monitoring for liver dysfunction, anemia, and vitamin D deficiency.
21.5 Treatment
Sun avoidance is the mainstay of treatment. A UV meter may be helpful to indicate the times and months when protective clothing, hats, gloves, umbrellas, and tinted windows are required. Topical sunscreens are of limited benefit. Oral betacarotene and alfamelanotide have been reported to improve sun tolerance.
21.6 Prognosis
Social isolation and lifestyle changes may significantly impair quality of life. A small subset of patients have severe progressive liver disease.